HRP20161608T1 - Modificirani tuberkulozni antigeni - Google Patents

Modificirani tuberkulozni antigeni Download PDF

Info

Publication number
HRP20161608T1
HRP20161608T1 HRP20161608TT HRP20161608T HRP20161608T1 HR P20161608 T1 HRP20161608 T1 HR P20161608T1 HR P20161608T T HRP20161608T T HR P20161608TT HR P20161608 T HRP20161608 T HR P20161608T HR P20161608 T1 HRP20161608 T1 HR P20161608T1
Authority
HR
Croatia
Prior art keywords
polypeptide
seq
modified
residues
rv3616c
Prior art date
Application number
HRP20161608TT
Other languages
English (en)
Croatian (hr)
Inventor
Normand Blais
James Brown
Anne-Marie Gelinas
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals Sa
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Glaxo Group Limited filed Critical Glaxosmithkline Biologicals Sa
Publication of HRP20161608T1 publication Critical patent/HRP20161608T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HRP20161608TT 2010-01-27 2011-01-27 Modificirani tuberkulozni antigeni HRP20161608T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29871010P 2010-01-27 2010-01-27
EP11700859.9A EP2528621B1 (en) 2010-01-27 2011-01-27 Modified tuberculosis antigens
PCT/EP2011/051158 WO2011092253A1 (en) 2010-01-27 2011-01-27 Modified tuberculosis antigens

Publications (1)

Publication Number Publication Date
HRP20161608T1 true HRP20161608T1 (hr) 2017-01-13

Family

ID=44318698

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161608TT HRP20161608T1 (hr) 2010-01-27 2011-01-27 Modificirani tuberkulozni antigeni

Country Status (25)

Country Link
US (2) US8932600B2 (enExample)
EP (1) EP2528621B1 (enExample)
JP (2) JP6010463B2 (enExample)
KR (1) KR20120129927A (enExample)
CN (1) CN102869372B (enExample)
AU (1) AU2011209399B2 (enExample)
BR (1) BR112012018669A2 (enExample)
CA (1) CA2786969C (enExample)
CO (1) CO6650338A2 (enExample)
CY (1) CY1119518T1 (enExample)
DK (1) DK2528621T3 (enExample)
EA (1) EA201290590A1 (enExample)
ES (1) ES2614266T3 (enExample)
HR (1) HRP20161608T1 (enExample)
HU (1) HUE031184T2 (enExample)
LT (1) LT2528621T (enExample)
MX (1) MX2012008790A (enExample)
MY (1) MY156697A (enExample)
PH (1) PH12012501550A1 (enExample)
PL (1) PL2528621T3 (enExample)
PT (1) PT2528621T (enExample)
SG (1) SG182573A1 (enExample)
SI (1) SI2528621T1 (enExample)
UA (1) UA110103C2 (enExample)
WO (1) WO2011092253A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2315597T3 (pl) 2008-07-25 2018-01-31 Glaxosmithkline Biologicals Sa Nowe kompozycje i sposoby
UA107330C2 (uk) 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування
HRP20181353T1 (hr) 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
MY156697A (en) * 2010-01-27 2016-03-15 Glaxosmithkline Biolog Sa Modified tuberculosis antigens
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013123579A1 (en) * 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
CN103467582A (zh) * 2012-06-08 2013-12-25 同济大学 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用
EP3013364B1 (en) 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
WO2015148960A1 (en) * 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN105675863B (zh) * 2016-02-17 2017-10-20 遵义医学院附属医院 一组耐多药结核病诊断标志物及其用途
CN109890411A (zh) 2016-06-16 2019-06-14 国际艾滋病疫苗行动组织公司 结核病组合物和治疗或预防结核病的方法
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals Sa métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
CN109966170B (zh) * 2018-02-13 2022-04-15 深圳高尚科美生物科技有限公司 包含生物大分子的柔性脂质体化妆品及其制备方法
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN116669707B (zh) * 2020-08-05 2025-11-14 杜兰教育基金管理委员会 体液样品中结核的检测方法
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1786412A (en) * 1929-11-20 1930-12-23 American Telephone & Telegraph Shielding arrangement
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
WO1991012325A1 (en) 1990-02-09 1991-08-22 E.I. Du Pont De Nemours And Company Htlv envelope antigenic segment
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH07501687A (ja) 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5551622A (en) 1994-07-13 1996-09-03 Yoon; Inbae Surgical stapler
AT402926B (de) 1994-12-05 1997-09-25 Hafslund Nycomed Pharma Heterocyclische amide, verfahren zu ihrer herstellung und verwendung
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
JPH11506332A (ja) 1995-06-02 1999-06-08 インサイト・ファーマスーティカルズ・インコーポレイテッド 全長ｃＤＮＡ配列を獲得する改良された方法
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
CN1154730C (zh) 1995-09-01 2004-06-23 科里克萨有限公司 用于结核病诊断的化合物和方法
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
JP4382160B2 (ja) 1995-09-01 2009-12-09 コリクサ コーポレイション 結核の免疫治療および診断のための化合物および方法
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
CZ126699A3 (cs) 1996-10-11 1999-09-15 Corixa Corporation Polypeptid obsahující antigenní část rozpustného antigenu M. tuberculosis nebo variantu uvedeného antigenu, molekula DNA kódující tento polypeptid, expresivní vektor, hostitelská buňka, způsoby diagnostiky infekce M. tuberculosis a diagnostické kity
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6544522B1 (en) 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
KR100824105B1 (ko) 1998-02-05 2008-04-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신접종을 위한 융합 단백질 및 조성물의 제조를 위해사용되는 ｍａｇｅ 군으로부터의 종양 관련 항원 유도체 및이들을 암호화하고 있는 핵산 서열
KR100797876B1 (ko) * 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
JP2003510370A (ja) 1999-10-07 2003-03-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
ATE526994T1 (de) * 2000-06-20 2011-10-15 Corixa Corp Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
CN1277843C (zh) 2001-02-22 2006-10-04 巴斯德研究院 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具
AU2002303135A1 (en) * 2001-03-13 2002-09-24 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
WO2003072633A1 (en) 2002-02-14 2003-09-04 Mitsui Chemicals, Inc. Polyester resin and catalyst for polyester production, process for producing polyester resin with the catalyst, polyester resin obtained with the catalyst, and hollow molded container comprising the polyester resin
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
MXPA04012443A (es) * 2002-06-11 2005-04-19 Glaxosmithkline Biolog Sa Composiciones inmunogenicas.
US7205259B2 (en) 2002-07-26 2007-04-17 Kimberly-Clark Worldwide, Inc. Absorbent binder desiccant composition and articles incorporating it
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
JP2008527947A (ja) 2005-01-19 2008-07-24 パンデュイット・コーポレーション 抑制コアを備えた通信チャンネル
US8475803B2 (en) * 2005-04-29 2013-07-02 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
BRPI0611347A2 (pt) 2005-04-29 2010-08-31 Glaxosmithline Biolog S A composicão farmacêutica, usos de uma proteìna de fusão mtb72f ou um fragmento imunogênico da mesma, e, de um ácido nucléico
PL1880008T3 (pl) 2005-05-03 2015-10-30 Inst Nat Sante Rech Med Wyrażanie białek mitochondrialnych przez wzmocnienie podejścia allotopowego
JP4468858B2 (ja) 2005-06-01 2010-05-26 オリンパスイメージング株式会社 データ符号化装置、データ符号化方法、プログラム
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7296798B2 (en) 2006-01-31 2007-11-20 Matt Overfield Gameboard, games played on board and methods of play requiring strategy and luck
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
PT2086582E (pt) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vacina compreendendo uma emulsão adjuvante óleo em água
US9297803B2 (en) * 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
PT2137210T (pt) * 2007-03-02 2017-01-09 Glaxosmithkline Biologicals Sa Novos métodos e composições
GB0716070D0 (en) * 2007-08-17 2007-09-26 Fusion Antibodies Ltd Diagnostic method and kit
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
FR2933552B1 (fr) 2008-07-04 2014-10-10 Centre Nat Rech Scient Circuit d'amplification d'un signal representant une variation de resistance d'une resistance variable et capteur correspondant
UA107330C2 (uk) 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
CN102549336B (zh) 2009-07-21 2014-11-26 库柏技术公司 将发光二极管(led)模块连接于散热器组件、反光件以及电路
MY156697A (en) * 2010-01-27 2016-03-15 Glaxosmithkline Biolog Sa Modified tuberculosis antigens
US9119754B2 (en) 2011-10-08 2015-09-01 Michael Dennis Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure
US9051890B2 (en) 2013-10-28 2015-06-09 Ford Global Technologies, Llc Method for estimating charge air cooler condensation storage with an intake oxygen sensor
US9903268B2 (en) 2015-04-02 2018-02-27 Ford Global Technologies, Llc Internal combustion engine with two-stage supercharging capability and with exhaust-gas aftertreatment arrangement, and method for operating an internal combustion engine
US9810514B2 (en) 2015-09-08 2017-11-07 Deufol Sunman Inc. Ammunition carrier consumer package

Also Published As

Publication number Publication date
US8932600B2 (en) 2015-01-13
US9200044B2 (en) 2015-12-01
US20120294882A1 (en) 2012-11-22
EP2528621B1 (en) 2016-09-21
CA2786969C (en) 2018-07-24
CA2786969A1 (en) 2011-08-04
CO6650338A2 (es) 2013-04-15
ES2614266T3 (es) 2017-05-30
EA201290590A1 (ru) 2013-03-29
KR20120129927A (ko) 2012-11-28
PL2528621T3 (pl) 2017-07-31
JP6503309B2 (ja) 2019-04-17
HUE031184T2 (en) 2017-06-28
PH12012501550A1 (en) 2012-10-22
BR112012018669A2 (pt) 2017-09-05
JP2016166193A (ja) 2016-09-15
US20150093414A1 (en) 2015-04-02
JP6010463B2 (ja) 2016-10-19
CY1119518T1 (el) 2018-03-07
MY156697A (en) 2016-03-15
AU2011209399B2 (en) 2014-04-10
PT2528621T (pt) 2016-12-20
SI2528621T1 (sl) 2017-01-31
SG182573A1 (en) 2012-08-30
EP2528621A1 (en) 2012-12-05
AU2011209399A1 (en) 2012-08-23
JP2013517783A (ja) 2013-05-20
MX2012008790A (es) 2012-08-17
DK2528621T3 (da) 2017-01-02
LT2528621T (lt) 2016-12-12
CN102869372A (zh) 2013-01-09
CN102869372B (zh) 2016-01-20
UA110103C2 (uk) 2015-11-25
WO2011092253A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
HRP20161608T1 (hr) Modificirani tuberkulozni antigeni
JP2013517783A5 (enExample)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
HRP20231437T1 (hr) Il-15 i il-15ralpha sushi domena na temelju modulokina
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
JP2015212284A5 (enExample)
HRP20220214T1 (hr) Imunomodulacijska sredstva
HRP20200503T1 (hr) Fuzijski proteini
HRP20160606T1 (hr) Pripravak mikrobakterijskih antigena
JP2017081939A5 (enExample)
HRP20240640T1 (hr) Kimerni proteini faktora viii i njihova upotreba
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
RU2021134101A (ru) Модифицированная j-цепь
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
JP2011530309A5 (enExample)
JP2015525217A5 (enExample)
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
FI3677591T3 (fi) Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
MX337456B (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores.
HRP20240226T1 (hr) Pripravci cjepiva koji sadrže protein vezivanja mutiranog faktora h
RU2015141214A (ru) Вакцины против Chlamydia sp.
HRP20170905T1 (hr) Antikancerogeni fuzijski protein
JP2015514132A5 (enExample)
HRP20171694T1 (hr) Novi pripravci i postupci